Next Article in Journal
Combining Sorafenib and Immunosuppression in Liver Transplant Recipients with Hepatocellular Carcinoma
Next Article in Special Issue
Synthesis and Anticancer Activity of Hybrid Molecules Based on Lithocholic and (5Z,9Z)-Tetradeca-5,9-dienedioic Acids Linked via Mono(di,tri,tetra)ethylene Glycol and α,ω-Diaminoalkane Units
Previous Article in Journal
Antifibrotic and Anti-Inflammatory Actions of α-Melanocytic Hormone: New Roles for an Old Player
Previous Article in Special Issue
Copper(II) and Zinc(II) Complexes with the Clinically Used Fluconazole: Comparison of Antifungal Activity and Therapeutic Potential
Article

Drug Repurposing: Dipeptidyl Peptidase IV (DPP4) Inhibitors as Potential Agents to Treat SARS-CoV-2 (2019-nCoV) Infection

School of Pharmacy, Health Sciences Campus, University of Waterloo, 200 University Avenue West, Waterloo, ON N2L 3G1, Canada
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2021, 14(1), 44; https://0-doi-org.brum.beds.ac.uk/10.3390/ph14010044
Received: 20 December 2020 / Revised: 2 January 2021 / Accepted: 6 January 2021 / Published: 8 January 2021
The current outbreak of severe acute respiratory distress syndrome (SARS) or nCOVID-19 pandemic, caused by the coronavirus-2 (CoV-2), continues to wreak havoc globally. As novel vaccines are being discovered and developed, small molecule drugs still constitute a viable treatment option for SARS-CoV-2 infections due to their advantages such as superior patient compliance for oral therapies, reduced manufacturing costs and ease of large scale distribution due to better stability and storage profiles. Discovering new drugs for SARS-CoV-2 infections is a time consuming and expensive proposition. In this regard, drug repurposing is an appealing approach which can provide rapid access to therapeutics with proven record of safety and efficacy. We investigated the drug repurposing potential of a library of dipeptidyl peptidase 4 (DPP4) inhibitors which are currently marketed for type-2 diabetes as treatment option for SARS-CoV-2 infections. These computational studies led to the identification of three marketed DPP4 inhibitors; gemigliptin, linagliptin and evogliptin as potential inhibitors of SARS-CoV-2 Mpro viral cysteine protease. In addition, our computational modeling shows that these drugs have the potential to inhibit other viral cysteine proteases from the beta coronavirus family, including the SAR-CoV Mpro and MERS-CoV CLpro suggesting their potential to be repurposed as broad-spectrum antiviral agents. View Full-Text
Keywords: drug repurposing; SARS-CoV-2 infection; dipeptidyl peptidase IV inhibitors; SARS-CoV-2 Mpro protomer; SARS-CoV-2 Mpro dimer; MERS-CoV CLpro; cysteine proteases; serine proteases; molecular docking; type-2 diabetes drug repurposing; SARS-CoV-2 infection; dipeptidyl peptidase IV inhibitors; SARS-CoV-2 Mpro protomer; SARS-CoV-2 Mpro dimer; MERS-CoV CLpro; cysteine proteases; serine proteases; molecular docking; type-2 diabetes
Show Figures

Graphical abstract

MDPI and ACS Style

Rao, P.P.N.; Pham, A.T.; Shakeri, A.; El Shatshat, A.; Zhao, Y.; Karuturi, R.C.; Hefny, A.A. Drug Repurposing: Dipeptidyl Peptidase IV (DPP4) Inhibitors as Potential Agents to Treat SARS-CoV-2 (2019-nCoV) Infection. Pharmaceuticals 2021, 14, 44. https://0-doi-org.brum.beds.ac.uk/10.3390/ph14010044

AMA Style

Rao PPN, Pham AT, Shakeri A, El Shatshat A, Zhao Y, Karuturi RC, Hefny AA. Drug Repurposing: Dipeptidyl Peptidase IV (DPP4) Inhibitors as Potential Agents to Treat SARS-CoV-2 (2019-nCoV) Infection. Pharmaceuticals. 2021; 14(1):44. https://0-doi-org.brum.beds.ac.uk/10.3390/ph14010044

Chicago/Turabian Style

Rao, Praveen P.N., Amy T. Pham, Arash Shakeri, Amna El Shatshat, Yusheng Zhao, Rahul C. Karuturi, and Ahmed A. Hefny 2021. "Drug Repurposing: Dipeptidyl Peptidase IV (DPP4) Inhibitors as Potential Agents to Treat SARS-CoV-2 (2019-nCoV) Infection" Pharmaceuticals 14, no. 1: 44. https://0-doi-org.brum.beds.ac.uk/10.3390/ph14010044

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop